Drugs / Lopinavir/Ritonavir
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT04455958 | May → Nov 2021 | COVID-19, cancer, hematopoietic and lymphoid cell neoplasm | OHSU Knight Cancer Institute | Withdrawn | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Lopinavir/Ritonavir | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04455958 ↗ |
| Route | Oral | “Given PO” NCT04455958 ↗ |